Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Production & Manufacturing
Return to: PBR Home | Production & Manufacturing
Today in Production & Manufacturing

Production & Manufacturing

FDA approves Avanir's Phase II trial of MDD candidate AVP-786 The US Food and Drug Administration (FDA) has accepted Avanir Pharmaceuticals' investigational new drug (IND) application for a Phase II trial evaluating the safety and efficacy of its next generation compound AVP-786. Production & Manufacturing > Process & Production > News

Latest Production & Manufacturing News by Sector

Select a sector from the list or browse by sector below:

Fine & Speciality Chemicals

CordenPharma agrees to purchase Peptisyntha from Solvay
By PBR Staff Writer
International Chemical Investors Group (ICIG) and the Solvay Group have embarked on an agreement, whereby ICIG will purchase Belgium-based Peptisyntha SA, a custom manufacturer of peptides for pharmaceutical use.
Production & Manufacturing > Fine & Speciality Chemicals > News
INVISTA, SilicoLife to develop new technologies for bio-derived processes
By PBR Staff Writer
INVISTA and SilicoLife, a computational biology company, have collaborated to develop new technologies that facilitate bio-derived processes for the production of industrial chemicals.
Production & Manufacturing > Fine & Speciality Chemicals > News

Process & Production

FDA accepts to review Adamis' NDA for Epinephrine pre-filled syringe
By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted for review Adamis Pharmaceuticals' new drug application (NDA) for the product, Epinephrine Injection, USP, 1:1000 (0.3mg Pre-filled single dose syringe) (PFS), for the emergency treatment of allergic reactions (Type I) including anaphylaxis.
Production & Manufacturing > Process & Production > News
FDA clears Fate Therapeutics' IND for PROHEMA in inherited metabolic disorders
By PBR Staff Writer
The US Food and Drug Administration (FDA) has cleared US-based biopharmaceutical firm Fate Therapeutics' investigational new drug application (IND) for the clinical development of PROHEMA in pediatric patients undergoing hematopoietic stem cell (HSC) transplantation for the treatment of inherited metabolic disorders (IMDs).
Production & Manufacturing > Process & Production > News

OTC

Axxess Pharma gets $2m financing to fulfill increased rate of purchase orders
Axxess Pharma Inc. is pleased to announce through its wholly owned subsidiary AllStar Health Brands Inc., that they have secured $2,000,000 USD in financing. Funds will be used to fulfill current purchase orders and increase marketing and inventory of products.
Production & Manufacturing > OTC > News
Inergetics completes Phase I development of therapeutic CBD line of products
Inergetics, a developer of nutritional supplements, has announced the successful completion of its first phase towards the formulation of its proprietary line of natural cannabidiol CBD-based nutritional supplements it is developing in partnership with Terra Tech Corp (TRTC).
Production & Manufacturing > OTC > News

Manufacturing

Pfizer agrees to acquire Baxter's vaccines business for $635m
By PBR Staff Writer
Pfizer has entered into a definitive agreement to acquire two commercially marketed vaccines and portion of related production facilities from Baxter International for $635m.
Production & Manufacturing > Manufacturing > News
Sunshine Biopharma forms Canadian subsidiary
Sunshine Biopharma, a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, has announced that it has formed Sunshine Biopharma Canada a Canadian wholly owned subsidiary for the purposes of conducting pharmaceutical business in Canada and elsewhere around the globe.
Production & Manufacturing > Manufacturing > News